NU 641 Advanced Clinical Pharmacology - Exam 1 Questions and
Answers and Explanations | Latest - Regis
1. Which phase of pharmacokinetics is most significantly impacted by the first-
pass effect when a drug is administered orally?
A. Distribution
B. Excretion
C. Metabolism
D. Absorption
Answer: C
Explanation: The first-pass effect refers to the rapid hepatic metabolism of a drug before it
reaches the systemic circulation, which occurs primarily in the liver (metabolism) after
absorption from the GI tract.
2. An NP is prescribing a drug with a high volume of distribution (Vd). This
characteristic implies that the drug:
A. Is highly water-soluble
B. Is likely highly lipid-soluble and penetrates tissues well
C. Remains primarily in the intravascular space
D. Has a very short half-life
Answer: B
,Explanation: A high volume of distribution indicates that the drug is distributed
extensively into the tissues rather than remaining in the plasma; this is typical of lipophilic
drugs.
3. Which Cytochrome P450 enzyme is responsible for metabolizing
approximately 50% of all clinically used drugs?
A. CYP2D6
B. CYP3A4
C. CYP2C19
D. CYP1A2
Answer: B
Explanation: CYP3A4 is the most prevalent enzyme in the liver and is involved in the
metabolism of about half of all marketed medications.
4. A patient is taking a drug that is a CYP450 inducer. What is the most likely
effect on a co-administered ‘substrate’ drug?
A. Increased plasma levels of the substrate
B. Increased risk of toxicity from the substrate
C. Decreased metabolism of the substrate
D. Decreased plasma levels of the substrate
Answer: D
,Explanation: Inducers increase the activity of metabolic enzymes, leading to faster
breakdown of substrate drugs and lower plasma concentrations.
5. What term describes the time required for the amount of drug in the body to
decrease by 50%?
A. Bioavailability
B. Steady state
C. Half-life
D. Clearance
Answer: C
Explanation: Half-life is defined as the time it takes for the plasma concentration of a drug
to reduce to half of its initial value.
6. How many half-lives are generally required for a drug to reach a steady-state
concentration in the plasma?
A. 1 to 2
B. 8 to 10
C. 4 to 5
D. Only 1 if a loading dose is given
Answer: C
Explanation: It typically takes 4 to 5 half-lives for a drug to reach steady state where the
rate of administration equals the rate of elimination.
, 7. A drug that binds to a receptor and produces a maximal biological response is
referred to as a:
A. Partial agonist
B. Full agonist
C. Antagonist
D. Inverse agonist
Answer: B
Explanation: Full agonists bind to receptors and mimic the endogenous regulatory
molecules to produce a maximum response.
8. Which type of antagonism is characterized by the antagonist binding
irreversibly to the receptor site?
A. Competitive antagonism
B. Physiological antagonism
C. Non-competitive antagonism
D. Pharmacokinetic antagonism
Answer: C
Explanation: Non-competitive antagonists bind irreversibly or to a different site, making it
impossible for the agonist to displace them regardless of concentration.
Answers and Explanations | Latest - Regis
1. Which phase of pharmacokinetics is most significantly impacted by the first-
pass effect when a drug is administered orally?
A. Distribution
B. Excretion
C. Metabolism
D. Absorption
Answer: C
Explanation: The first-pass effect refers to the rapid hepatic metabolism of a drug before it
reaches the systemic circulation, which occurs primarily in the liver (metabolism) after
absorption from the GI tract.
2. An NP is prescribing a drug with a high volume of distribution (Vd). This
characteristic implies that the drug:
A. Is highly water-soluble
B. Is likely highly lipid-soluble and penetrates tissues well
C. Remains primarily in the intravascular space
D. Has a very short half-life
Answer: B
,Explanation: A high volume of distribution indicates that the drug is distributed
extensively into the tissues rather than remaining in the plasma; this is typical of lipophilic
drugs.
3. Which Cytochrome P450 enzyme is responsible for metabolizing
approximately 50% of all clinically used drugs?
A. CYP2D6
B. CYP3A4
C. CYP2C19
D. CYP1A2
Answer: B
Explanation: CYP3A4 is the most prevalent enzyme in the liver and is involved in the
metabolism of about half of all marketed medications.
4. A patient is taking a drug that is a CYP450 inducer. What is the most likely
effect on a co-administered ‘substrate’ drug?
A. Increased plasma levels of the substrate
B. Increased risk of toxicity from the substrate
C. Decreased metabolism of the substrate
D. Decreased plasma levels of the substrate
Answer: D
,Explanation: Inducers increase the activity of metabolic enzymes, leading to faster
breakdown of substrate drugs and lower plasma concentrations.
5. What term describes the time required for the amount of drug in the body to
decrease by 50%?
A. Bioavailability
B. Steady state
C. Half-life
D. Clearance
Answer: C
Explanation: Half-life is defined as the time it takes for the plasma concentration of a drug
to reduce to half of its initial value.
6. How many half-lives are generally required for a drug to reach a steady-state
concentration in the plasma?
A. 1 to 2
B. 8 to 10
C. 4 to 5
D. Only 1 if a loading dose is given
Answer: C
Explanation: It typically takes 4 to 5 half-lives for a drug to reach steady state where the
rate of administration equals the rate of elimination.
, 7. A drug that binds to a receptor and produces a maximal biological response is
referred to as a:
A. Partial agonist
B. Full agonist
C. Antagonist
D. Inverse agonist
Answer: B
Explanation: Full agonists bind to receptors and mimic the endogenous regulatory
molecules to produce a maximum response.
8. Which type of antagonism is characterized by the antagonist binding
irreversibly to the receptor site?
A. Competitive antagonism
B. Physiological antagonism
C. Non-competitive antagonism
D. Pharmacokinetic antagonism
Answer: C
Explanation: Non-competitive antagonists bind irreversibly or to a different site, making it
impossible for the agonist to displace them regardless of concentration.
